CRL vs NVS
Charles River Laboratories vs Novartis AG — AI-powered side-by-side comparison
CRL
Charles River Laboratories
61
Buy
VS
| Metric | CRL | NVS |
|---|
| AI Score |
61
|
72
|
| Price |
$297.55
|
$160.01
|
| P/E Ratio |
-61.69×
|
23.98×
|
| ROE |
-4.6%
|
30.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
32.2%
|
74.3%
|
| Debt / Equity |
1.07×
|
1.18×
|
| Dividend Yield |
0.0%
|
2.9%
|
| RSI (14) |
79.8
|
57.9
|
| Beta |
1.376
|
0.462
|
| Expected Upside |
+1.4%
|
+1.6%
|
AI Committee View
Current Innellis committee reasoning for CRL versus NVS.
NVS leads by 11 points.
NVS scores 72/100 (Buy) versus CRL at 61/100 (Buy).
CRL Committee View
80% agreement
5 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — 5 consecutive earnings beats -- consistent execution. Risk Analyst remains cautious — bollinger bandwidth of 35.8% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- RSI at 80 is in overbought territory — Technical
- Weekly RSI at 87 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 35.8% signals elevated volatility — Risk
NVS Committee View
100% agreement
5 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Risk/reward is unfavorable: 8.0% downside vs 1.6% upside.